We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · July 25, 2022

Immune Checkpoint Blockade for Melanoma In-Transit With or Without Nodal Metastases

European Journal of Cancer


Additional Info

European Journal of Cancer
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study
Eur. J. Cancer 2022 Jul 01;169(2022)210-222, CJ Holmberg, L Ny, TJ Hieken, MS Block, MJ Carr, VK Sondak, C Örtenwall, D Katsarelias, F Dimitriou, AM Menzies, RP Saw, A Rogiers, RJ Straker, G Karakousis, R Applewaite, L Pallan, D Han, JT Vetto, DE Gyorki, EN Tie, MG Vitale, PA Ascierto, R Dummer, J Cohen, JY Hui, J Schachter, N Asher, H Helgadottir, H Chai, H Kroon, B Coventry, LD Rothermel, J Sun, MS Carlino, Z Duncan, K Broman, J Weber, AY Lee, RS Berman, J Teras, DW Ollila, GV Long, JS Zager, A van Akkooi, R Olofsson Bagge

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading